ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

AN OVERVIEW OF HELICOBACTER PYLORI, COMPLICATIONS, AND MANAGEMENT APPROACHES

AUTHORS:

Hussain Ali Alhazmi, Deena Nabil Bedaiwi, Leena Nabil Bedaiwi, Awath Fahim Alsulami, Abdulaziz Mesfer Sanat Alotaibi, Thamer Saud Marshad Aloqaili, Mohammed Saaduddin Sahibzada, Rehab Mohammed Aldossari, Muath Abdullah Alhashim, Ghady Ibrahim Alhayazea, Shouq Shilash Alshammari

ABSTRACT:

Helicobacter pylori, is a gram-negative, spiral bacterium located on the epithelial surface area of the stomach. The main Goal of our study was to overview the management approaches toward Helicobacter pylori infection, and also to discuss the complications occurring during this bacterial infection, such as antibiotics resistance. Medline, PubMed and Embase databases were searched for treatment options and approaches of Helicobacter pylori for the period to the end 2018. Several studies have shown that the updates on the management procedures of H. pylori, and different guidelines were reviewed for more evidence about the steps on treatment of H. pylori infection. including 2 antibiotics and a proton-pump inhibitor proposed as the first-line program. probiotics treatment, are an alternative therapy that discovered to be extremely useful treatment line of H. pylori infection. Levofloxacin containing triple treatment are recommended as rescue treatment for infection of H. pylori after defeat of first-line treatment. The rapid acquisition of antibiotic resistance minimizes the effectiveness of any regimens involving these remedies. Therefore, adding probiotic to the medications, developing anti-H. pylori phytomedicine or photodynamic therapy, and accomplishing a successful H. pylori vaccine might have the appealing to present synergistic or additive consequence against H. pylori, since each of them apply different results.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.